Tizanidine Should Be Avoided During Breastfeeding
Tizanidine is not recommended for use while breastfeeding due to lack of safety data and its lipophilic properties that suggest likely passage into breast milk, with potential for infant sedation and CNS depression.
FDA Label Evidence
The FDA drug label explicitly states: "It is not known whether tizanidine is excreted in human milk, although as a lipid soluble drug, it might be expected to pass into breast milk" 1. This lack of human data, combined with the drug's pharmacologic properties, creates significant concern for infant safety.
Key Pharmacologic Concerns
Tizanidine's properties make it particularly problematic during lactation:
- Lipid solubility: Facilitates transfer into breast milk
- CNS depressant effects: Risk of infant sedation, drowsiness, and poor feeding
- Alpha-2 adrenergic agonist activity: Central nervous system effects that could impact the infant
- Long half-life considerations: Potential for accumulation with repeated maternal dosing
Expert Consensus
A 2013 systematic review of migraine medications during breastfeeding specifically lists tizanidine among preventive medications that are NOT recommended 2. This represents expert consensus from the American Headache Society's Women's Special Interest Section after reviewing multiple authoritative sources including LactMed, Hale's Medications and Mothers' Milk, and the American Academy of Pediatrics guidelines.
Clinical Decision-Making Algorithm
When a breastfeeding woman requires muscle relaxation:
First-line alternatives: Consider physical therapy, NSAIDs (ibuprofen, diclofenac), or acetaminophen, all of which are safe during breastfeeding 3, 4
If muscle relaxant necessary: Baclofen has more safety data in lactation and should be considered instead 5
If tizanidine absolutely required:
- Discuss risks with patient including potential infant sedation
- Use lowest effective dose
- Monitor infant closely for drowsiness, poor feeding, hypotonia
- Consider temporary interruption of breastfeeding or pumping and discarding milk
Important Caveats
- No human lactation studies exist for tizanidine, making risk assessment based entirely on theoretical concerns and pharmacologic properties
- The drug's sedative effects could be additive with other CNS depressants the mother may be taking 1
- Women taking oral contraceptives have 50% reduced clearance of tizanidine, potentially increasing milk concentrations 1
Practical Considerations
The absence of safety data is itself a critical finding. Unlike medications with established safety profiles during lactation (morphine, ibuprofen, local anesthetics), tizanidine lacks the clinical experience necessary to reassure about infant safety 3, 4. When evidence is absent for a CNS-active, lipophilic medication, the prudent clinical approach is avoidance.